0
Abstract: Slide Presentations |

A PROSPECTIVE EVALUATION OF BETA2-ADRENERGIC RECEPTOR POLYMORPHISMS AND ASTHMA EXACERBATIONS FREE TO VIEW

Wayne Anderson, PhD*; Steven Yancey, MS; Amanda Emmett, MS; Hector Ortega, MD
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest


Chest. 2008;134(4_MeetingAbstracts):s43003. doi:10.1378/chest.134.4_MeetingAbstracts.s43003
Text Size: A A A
Published online

Abstract

PURPOSE:Some studies have reported that Arg16Gly and Gln27Glu polymorphisms in the β2-adrenergic receptor (ADRB2) are associated with modulating responses to β2-agonist therapy for asthma. We evaluated ADRB2 polymorphisms across the entire gene, for their association with asthma exacerbations in subjects treated with salmeterol (SAL) or fluticasone propionate/salmeterol via Diskus (FSC).

METHODS:Four hundred and eighty-five subjects (>12 years) entered an 8-week open-label prn albuterol run-in followed by an 8-week prn ipratropium run-in prior to randomization to 16–weeks of treatment with SAL (50mcg BID) or FSC (100/50mcg BID). Exacerbations were defined as worsening asthma requiring an ED visit, hospitalization, or medication beyond the protocol. Eleven SNPs and a poly-C repeat in the 3’ region were genotyped or sequenced.

RESULTS:Results were compared between genotypes during the combined open-label periods and between genotypes during treatment with SAL or FSC. During the 16-week open label run-in periods there was 1 statistically significant marker at position -1818 where the frequency of exacerbations was 0.010 and 0.057 (p=0.005) for the A/A and T/T genotypes respectively. For the Arg16Gly genotypes the exacerbation frequency for Arg/Arg was 0.056 vs Gly/Gly of 0.013 (p=0.057). There were no associations observed in the poly-C region when grouped by subjects with <12 repeats vs subjects with ≥12. Once subjects entered the double-blind treatment period with SAL or FSC, exacerbation frequencies markedly decreased in the FSC group, with no significant genotype effects. Similarly in the SAL treatment arm, no genotype effects were observed.

CONCLUSION:Polymorphisms in the ADRB2 do not appear to be strong predictors of asthma exacerbations. Treatment with FSC markedly decreased asthma exacerbations across all ADRB2 genotypes.

CLINICAL IMPLICATIONS:The results reported here depict the lack of pharmacogenetic associations with exacerbations, but further study is needed in higher risk populations such as African Americans and patients with severe asthma.(SFA100062).

DISCLOSURE:Wayne Anderson, Employee GSK; No Product/Research Disclosure Information

Tuesday, October 28, 2008

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543